http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2341361-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3f1ebd2c7fdd1c358aa0246a13d70af4 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5029 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-566 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5061 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-566 |
| filingDate | 1999-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_15232c38ee4c38179737c93c2a373349 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_04c000dede243a590de72f2f3699b59a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_49886b10d3ec4827d9d202791e19c24d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f9d0a42618a55973eba72347ee104142 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_27f783e28cb2f08d05678ebf259ec9e6 |
| publicationDate | 2000-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2341361-A1 |
| titleOfInvention | Prevention of cell migration initiation with cmv us28 receptor antagonists |
| abstract | There is disclosed an assay system for determining therapeutic activity for treating restenosis, atherosclerosis, chronic rejection syndrome and graft versus host disease (GVHD) by measuring inhibition of cell migration activity in smooth muscle cells expressing a US28 receptor from the CMV genome. Specifically, there is disclosed a method for measuring inhibition of cell migration in isolated cells transfected with US28 or infected with CMV and stimulated with a ligand. There is further disclosed a method for treating atherosclerosis, restenosis, chronic rejection syndrome and graft versus host disease (GVHD), comprising administering an effective amount of an agent that is a US28 receptor antagonist, wherein a US28 receptor antagonist comprises an inhibitor compound that prevents transduction of US28 receptor signal stimulated by a US28 receptor ligand, wherein a US28 receptor ligand is selected from the group consisting of RANTES, MIP-1.alpha. and MCP. The invention further provides a method for treating restenosis, atherosclerosis, chronic rejection syndrome and GVHD by administering KHSV encoded vMIP-2, fractalkine or herbimycin. |
| priorityDate | 1998-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 71.